Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Zillow Group Inc Class A — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while Zillow Group Inc Class A trades at $32.92 (market cap $7.31B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.3× Zillow Group Inc Class A's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals.
| VRTX | ZG | |
|---|---|---|
Market Cap | $134.06B | $7.31B |
Sector | Health | Media |
52-Week High | $557.96 | $86.76 |
52-Week Low | $376.62 | $29.14 |
Enterprise Value | $128.18B | $7.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Zillow Group (ZG) trades at $33.03, down 6.48% in the last session, with technical indicators showing a bearish trend as the price approaches key support near $32. Fundamentally, the company shows improving revenue growth to $2.58 billion in 2025 and a return to profitability with net income of $23 million, though valuation remains elevated with a P/E of 143.57. Recent news highlights Zillow's strategic shift to an integrated transaction platform and resolution of FTC litigation.
The outlook is mixed: analyst consensus targets $47.56 (44% upside) with 47% buy ratings, but near-term housing market softness and high valuation pose risks. The stock offers growth potential through platform monetization, yet investors face execution risks and macroeconomic headwinds in the real estate sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
